Trial Profile
A randomized trial to compare skin toxicity of Gefitinib versus Erlotinib in patients with unresectable locally advanced or metastatic Non Small Cell Lung Cancer (NSCLC) who failed previous platinum based chemotherapy.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 12 Nov 2019
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 05 Mar 2018 New trial record